Lucid is planning on bringing #CheckYourFoodTube events to more ex-NFL stars in cities across the U.S., with a goal of ...

Gilead Sciences is wasting no time in promoting worldwide access to its twice-yearly pre-exposure prophylaxis (PrEP) HIV ...

While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi ...

Roughly a year and a half after the introduction of a damning shareholder lawsuit, Amgen has lost its bid to toss the case ...

As Eli Lilly has surged to become the most valuable company in biopharma—with a market cap now more than twice that of ...

After a relatively quiet stretch, Aspen Neuroscience is rolling out a major upgrade to its in-house manufacturing. | Aspen is ...

Under the new cooperation deal, Recipharm gets access to Exela’s manufacturing plant in Lenoir, North Carolina. Exela is ...

Looking back over Verrica's second-quarter financial results released in August, it's easy to spot the problem. Selling, ...

No large pharma company has traversed this decade's ups and downs quite like Pfizer. | No large pharma company has traversed ...

On the same day that Johnson & Johnson confirmed layoffs at its home base in New Jersey | Officials in Wilson, North Carolina ...

Following a similar move in March, Pfizer is offloading another tranche of Haleon shares. | Pfizer has sold 640 million ...

After experiencing a series of ups and downs in recent years, the biopharma contracting business is gearing up for a rebound ...